Gaithersburg, MD, January 7, 2016 – MaxCyte® Inc., a world leader in the discovery, development, and manufacture of innovative cell-based medicines, today announces that Chief Executive Officer, Doug Doerfler, will present at Biotech Showcase 2016 in San Francisco, CA.
Mr. Doerfler will present on Monday, 11 January 2016 at 10:30 PDT. During his presentation, he will discuss Maxcyte’s pipeline of cell therapy programs, its partnerships and customers for its best in class cell modification technology which is used in the discovery, development, and manufacture of small molecule, biologic, and cell-based medicines.
Please visit http://www.ebdgroup.com/bts/index.php for full information about the conference.
Ends
MaxCyte
+1 301 944 1645
Meg Duskin, Marketing Communications Manager
mduskin@maxcyte.com
Consilium Strategic Communications
+44 (0)20 3709 5700
Chris Welsh / Mary-Jane Elliot / Ivar Milligan / Lindsey Neville
maxcyte@consilium-comms.com
About MaxCyte
MaxCyte is the leader in driving the next generation of cell-based medicines with flow electroporation. MaxCyte’s best in class cell modification technology is used in the discovery, development, and manufacture of small molecule, biologic, and cell-based medicines. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of (co)transfected cells for cellular therapy, genetic engineering, protein and antibody production, rapid response vaccine development, and cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale. In addition to being used in 9 out of the top 10 companies worldwide, MaxCyte currently has clinical, pre-clinical-partnered, and proprietary products under development and is involved in more than a dozen clinical trials.
Mr. Doerfler will present on Monday, 11 January 2016 at 10:30 PDT. During his presentation, he will discuss Maxcyte’s pipeline of cell therapy programs, its partnerships and customers for its best in class cell modification technology which is used in the discovery, development, and manufacture of small molecule, biologic, and cell-based medicines.
Please visit http://www.ebdgroup.com/bts/index.php for full information about the conference.
Ends
MaxCyte
+1 301 944 1645
Meg Duskin, Marketing Communications Manager
mduskin@maxcyte.com
Consilium Strategic Communications
+44 (0)20 3709 5700
Chris Welsh / Mary-Jane Elliot / Ivar Milligan / Lindsey Neville
maxcyte@consilium-comms.com
About MaxCyte
MaxCyte is the leader in driving the next generation of cell-based medicines with flow electroporation. MaxCyte’s best in class cell modification technology is used in the discovery, development, and manufacture of small molecule, biologic, and cell-based medicines. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of (co)transfected cells for cellular therapy, genetic engineering, protein and antibody production, rapid response vaccine development, and cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale. In addition to being used in 9 out of the top 10 companies worldwide, MaxCyte currently has clinical, pre-clinical-partnered, and proprietary products under development and is involved in more than a dozen clinical trials.
